- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of MedImmune FluMist Introduction
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of MedImmune FluMist Introduction will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The MedImmune FluMist Introduction VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The MedImmune FluMist Introduction VRIO Analysis shows that the financial resources of MedImmune FluMist Introduction are highly valuable as these help in investing into external opportunities that arise. These also help MedImmune FluMist Introduction in combating external threats.
- According to the VRIO Analysis of MedImmune FluMist Introduction, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The MedImmune FluMist Introduction VRIO Analysis shows that MedImmune FluMist Introduction's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of MedImmune FluMist Introduction's products.
- According to the VRIO Analysis of MedImmune FluMist Introduction, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for MedImmune FluMist Introduction. These patents also provide MedImmune FluMist Introduction with licensing revenue when it licenses these patents out to other manufacturers.
- The MedImmune FluMist Introduction VRIO Analysis shows that MedImmune FluMist Introduction’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for MedImmune FluMist Introduction. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of MedImmune FluMist Introduction, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The MedImmune FluMist Introduction VRIO Analysis shows that the research and development at MedImmune FluMist Introduction is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for MedImmune FluMist Introduction. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of MedImmune FluMist Introduction are found to be rare according to the VRIO Analysis of MedImmune FluMist Introduction. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by MedImmune FluMist Introduction VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as MedImmune FluMist Introduction and inhibit competitive advantage. This means that the local food products result in competitive parity for MedImmune FluMist Introduction. As this resource is valuable, MedImmune FluMist Introduction can still make use of this resource.
- The employees of MedImmune FluMist Introduction are a rare resource as identified by the VRIO Analysis of MedImmune FluMist Introduction. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of MedImmune FluMist Introduction are a rare resource as identified by the MedImmune FluMist Introduction VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows MedImmune FluMist Introduction to use them without interference from the competition.
- The distribution network of MedImmune FluMist Introduction is a rare resource as identified by the VRIO Analysis of MedImmune FluMist Introduction. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of MedImmune FluMist Introduction. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of MedImmune FluMist Introduction are costly to imitate as identified by the MedImmune FluMist Introduction VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of MedImmune FluMist Introduction. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by MedImmune FluMist Introduction provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of MedImmune FluMist Introduction are also not costly to imitate as identified by the MedImmune FluMist Introduction VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from MedImmune FluMist Introduction by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of MedImmune FluMist Introduction a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of MedImmune FluMist Introduction are very difficult to imitate as identified by the VRIO Analysis of MedImmune FluMist Introduction. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of MedImmune FluMist Introduction is also very costly to imitate by competition as identified by the MedImmune FluMist Introduction VRIO Analysis. This has been developed over the years gradually by MedImmune FluMist Introduction. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of MedImmune FluMist Introduction are organised to capture value as identified by the VRIO Analysis of MedImmune FluMist Introduction. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for MedImmune FluMist Introduction.
- The Patents of MedImmune FluMist Introduction are not well organised as identified by the MedImmune FluMist Introduction VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if MedImmune FluMist Introduction starts selling patented products before the patents expire.
- The distribution network of MedImmune FluMist Introduction is organised as identified by the VRIO Analysis of MedImmune FluMist Introduction. MedImmune FluMist Introduction uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for MedImmune FluMist Introduction.
From the VRIO Analysis of MedImmune FluMist Introduction, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of MedImmune FluMist Introduction is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Chen An
5.0
The paper that was delivered to me was according to Chicago style. Thank you for affordable prices!
Deniz Zemir
5.0
I like the professionalism and the commitment of this service to work. I would like to advise this service to everyone.
Xie Xu
5.0
I didn't know the tiniest idea of the topic. Fast and professional. Thank you for giving me the assignment as per the requirements.
Steph Angus
5.0
Order this service and I guarantee that you won't regret your decision because this service cares for its customers. Fixed time delivery and affordable costs. Thank you!
Next Articles
- Mindray Medical International Limited: Going Global From China Vrio Analysis
- I've Got Rhythm: Selling Cardiac Rhythm Management Devices Vrio Analysis
- GE Healthcare India (B): The Product Innovation Journey Vrio Analysis
- Cialis Lifecycle Management: Lilly's BPH Dilemma Vrio Analysis
- Merck Medco: Vertical Integration In The Pharmaceutical Industry Vrio Analysis
- Gilead: Hepatitis C Access Strategy (A) Vrio Analysis
- Population Services International: The Social Marketing Project In Bangladesh, Video Vrio Analysis
- Glaxo And Zantac: The Life, Times, And Near Death Of The World's Best Selling Drug Vrio Analysis
- Synthes Vrio Analysis
- Terumo (A) Vrio Analysis
Previous Articles
- Pfizer And AstraZeneca: Marketing An Acquisition (B) Vrio Analysis
- Nin Jiom: Selling Traditional Chinese Medicine In Modern Hong Kong Vrio Analysis
- Pharmaceutical Switching Vrio Analysis
- Fighting AIDS And Pricing Drugs Vrio Analysis
- Med Mart: Transitioning The Business Model (A) Vrio Analysis
- ZS Associates: Sales Force Sizing Vrio Analysis
- 3M Chile: Health Care Products (B) Vrio Analysis
- Marketing Antidepressants: Prozac And Paxil, Spanish Version Vrio Analysis
- Dendrite International Vrio Analysis
- Medi Cult: Pricing A Radical Innovation Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!